Clinical Trial Update: Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for AK104, a PD-1/CTLA-4 bispecific antibody, in selected advanced solid tumors and melanoma showing safety and efficacy signals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Solid Tumors

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Advanced Solid Tumors, Melanoma | Phase 1, Phase 2 | Status: COMPLETED